More men are getting checked for prostate cancer and realising they have the disease at an early stage, but charity Prostate ...

Diagnoses of prostate cancer overtook breast cancer in 2022 and 2023, according to the charity Prostate Cancer UK.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

More than 50,000 men were diagnosed with prostate cancer in England in 2023 - but a leading charity claims more needs to be ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...